HSPA5 and hepatocellular carcinoma: In another study, a combination of sorafenib and exosomes modified with glucose-regulated protein 78 (GRP78) sensitizes sorafenib-resistant HCC cells and overcomes drug resistance by targeting GRP18 in HCC cells [186].